|Day's Range||2.83 - 2.95|
|52 Week Range||0.70 - 3.50|
|PE Ratio (TTM)||-5.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||15.91|
The members of congress introduced a bill related to the talk last week. A quartet of Democratic members of Congress introduced a bill last week in harmony with President Donald Trump’s campaign promises of lowering prescription drug costs. Entitled the Improving Access to Affordable Prescription Drugs Act, the 128-page bill aims to overhaul what many view as a broken system that has seen bipartisan outrage over skyrocketing prices.
Novogen Ltd (NASDAQ: NVGN ) is pleased to confirm receipt of $4.4m from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2016. These funds will be ...
- Recent in-licensing of GDC-0084 and advancement of Cantrixil to phase I represent transformation of Novogen to clinical-stage organisation; recent appointments of Chief Medical Officer and Head of CMC ...